Press Releases April 14, 2026 08:00 PM

Wintrust Financial Corporation Announces Cash Dividends

Wintrust Financial Corporation Declares Quarterly Common and Preferred Stock Dividends

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
WTFC

Wintrust Financial Corporation's Board of Directors has approved a quarterly cash dividend of $0.55 per share on its common stock, payable May 28, 2026, and a cash dividend on its Series F preferred stock, payable July 15, 2026. The company operates multiple community banks and financial services across several Midwest and Florida regions, with total assets of $71.1 billion.

Wintrust Financial Corporation Announces Cash Dividends
WTFC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Quarterly cash dividend of $0.55 per common share declared, signaling strong liquidity and shareholder returns.
  • Dividend approved for Series F preferred stock, enhancing appeal to income-focused investors.
  • Wintrust operates over 200 retail banking locations and diverse financial service units impacting regional banking and financial services sectors.

ROSEMONT, Ill., April 15, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Wintrust Financial Corporation (“Wintrust” or the “Company”) (Nasdaq: WTFC) has approved a quarterly cash dividend of $0.55 per share of outstanding common stock. The dividend is payable on May 28, 2026, to shareholders of record as of May 14, 2026.

Additionally, the Company’s Board of Directors approved a cash dividend on outstanding shares of the Company’s 7.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series F. The dividend is payable on July 15, 2026, to shareholders of record as of July 1, 2026.

About Wintrust

Wintrust is a financial holding company with $71.1 billion in assets whose common stock is traded on the Nasdaq Global Select Market. Guided by its “Different Approach, Better Results®” philosophy, Wintrust offers the sophisticated resources of a large bank while providing a community banking experience to each customer. Wintrust operates more than 200 retail banking locations through 16 community bank subsidiaries in the greater Chicago, southern Wisconsin, west Michigan, northwest Indiana, and southwest Florida market areas. In addition, Wintrust operates various non-bank business units, providing residential mortgage origination, wealth management, commercial and life insurance premium financing, short-term accounts receivable financing/outsourced administrative services to the temporary staffing services industry, and qualified intermediary services for tax-deferred exchanges. For more information, please visit wintrust.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that such statements are predictions and that actual events or results may differ materially. Wintrust's expected financial results or other plans are subject to a number of risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" and the forward-looking statement disclosure contained in Wintrust's Annual Report on Form 10-K for the most recently ended fiscal year. Forward-looking statements speak only as of the date made and Wintrust undertakes no duty to update the information.

FOR MORE INFORMATION CONTACT:
David A. Dykstra, Vice Chairman & Chief Operating Officer
(847) 939-9000
Amy Yuhn, Executive Vice President, Communications
(847) 939-9591
Website address: www.wintrust.com


Risks

  • Forward-looking statements highlight potential risks and uncertainties that could impact actual results, including economic or regulatory changes.
  • Dependence on regional economic conditions in the Midwest and Florida markets may affect future financial performance.
  • As a financial institution, exposure to credit risk, interest rate fluctuations, and competitive banking environment present ongoing challenges.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026